SCHEMBL549112

SCHEMBL549112

CC(C)(C)c1cc(C23CC4CC(CC(C4)C2)C3)c(OCC2CO2)cc1C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.39
ALDH1A1 P00352 4/20 0.39
TP53 P04637 3/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HIF1A Q16665 2/20 0.39
CYP1A2 P05177 1/20 0.39
PPARG P37231 1/20 0.39
GLA P06280 1/20 0.38
CYP3A4 P08684 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPK1 P28482 1/20 0.33
VDR P11473 1/20 0.32
IDO1 P14902 1/20 0.32
TDO2 P48775 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
IKBKB O14920 2/20 0.30
RARA P10276 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL550068 0.91 TSHR (0.40) TSHRALDH1A1TP53MAPTHPGD
SCHEMBL549747 0.88 TSHR (0.36) TSHRALDH1A1TP53MAPTHPGD
SCHEMBL548846 0.88 ALDH1A1 (0.42) TSHRALDH1A1TP53MAPTHPGD
SCHEMBL548767 0.85 ALDH1A1 (0.41) TSHRALDH1A1TP53MAPTHPGD
SCHEMBL3767299 0.85 ALDH1A1 (0.41) TSHRALDH1A1TP53MAPTHPGD
SCHEMBL548839 0.84 ALDH1A1 (0.44) TSHRALDH1A1TP53MAPTHPGD
SCHEMBL549875 0.84 ALDH1A1 (0.41) TSHRALDH1A1TP53MAPTHPGD
SCHEMBL548706 0.82 ALDH1A1 (0.42) TSHRALDH1A1TP53MAPTHPGD
SCHEMBL549748 0.82 TSHR (0.36) TSHRALDH1A1TP53MAPTHPGD
SCHEMBL549597 0.82 ALDH1A1 (0.44) TSHRALDH1A1TP53MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110614-B2 Adamantane derivative, method for producing the same, and resin composition containing adamantane derivative IDEMITSU KOSAN CO., LTD. (JP) 2012-02-07 US disclosed
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2010-03-04 US disclosed
EP-2090563-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE IDEMITSU KOSAN COMPANY LIMITED (JP) 2009-08-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056663-A1 ADAMANTANE DERIVATIVE, METHOD FOR PRODUCING THE SAME, AND RESIN COMPOSITION CONTAINING ADAMANTANE DERIVATIVE ARCN1, RTN3, CHRNA3 TSHR 4644/4885ALDH1A1 312/4885TP53 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.